Jacobson Mark's Insider Trades & SAST Disclosures
Jacobson Mark's most recent trade in Axsome Therapeutics Inc was a trade of 10,875 Employee Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Feb. 21, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Jacobson Mark.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Axsome Therapeutics Inc | Mark Jacobson | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2025 | 10,875 | 10,875 | - | - | Employee Stock Option (Right to Buy) | |
| Axsome Therapeutics Inc | Mark Jacobson | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2025 | 10,769 | 10,769 | - | - | Performance Stock Units | |
| Axsome Therapeutics Inc | Mark Jacobson | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2025 | 10,769 | 10,769 | - | - | Restricted Stock Units | |
| Axsome Therapeutics Inc | Mark Jacobson | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Aug 2024 | 47,739 | 0 | - | - | Stock Option (Right to Buy) | |
| Axsome Therapeutics Inc | Mark Jacobson | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.04 per share. | 09 Aug 2024 | 47,739 | 53,522 (0%) | 0% | 4.0 | 192,866 | Common Stock |
| Axsome Therapeutics Inc | Mark Jacobson | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 84.26 per share. | 09 Aug 2024 | 47,739 | 5,783 (0%) | 0% | 84.3 | 4,022,488 | Common Stock |
| Axsome Therapeutics Inc | Mark Jacobson | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.30 per share. | 29 May 2024 | 13,693 | 13,693 (0%) | 0% | 1.3 | 17,801 | Common Stock |
| Axsome Therapeutics Inc | Mark Jacobson | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 May 2024 | 13,693 | 0 | - | - | Stock Option (Right to Buy) | |
| Axsome Therapeutics Inc | Mark Jacobson | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 74.31 per share. | 29 May 2024 | 7,910 | 5,783 (0%) | 0% | 74.3 | 587,813 | Common Stock |
| Axsome Therapeutics Inc | Mark Jacobson | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.30 per share. | 01 Apr 2024 | 24,662 | 24,662 (0%) | 0% | 1.3 | 32,061 | Common Stock |
| Axsome Therapeutics Inc | Mark Jacobson | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2024 | 24,662 | 0 | - | - | Stock Option (Right to Buy) | |
| Axsome Therapeutics Inc | Mark Jacobson | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 77.24 per share. | 01 Apr 2024 | 24,662 | 0 (0%) | 0% | 77.2 | 1,904,942 | Common Stock |
| Axsome Therapeutics Inc | Jacobson Mark | CHIEF OPERATING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2024 | 32,825 | 32,825 | - | - | Employee Stock Option (Right to Buy) | |
| Axsome Therapeutics Inc | Mark Jacobson | CHIEF OPERATING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2024 | 18,027 | 18,027 | - | - | Restricted Stock Units | |
| Axsome Therapeutics Inc | Mark Jacobson | CHIEF OPERATING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2023 | 41,424 | 41,424 | - | - | Employee Stock Option (Right to Buy) | |
| Axsome Therapeutics Inc | Mark Jacobson | CHIEF OPERATING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2023 | 23,491 | 23,491 | - | - | Restricted Stock Units | |
| Axsome Therapeutics Inc | Mark Jacobson | CHIEF OPERATING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2022 | 89,405 | 89,405 | - | - | Employee Stock Option (Right to Buy) | |
| Axsome Therapeutics Inc | Mark Jacobson | CHIEF OPERATING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2022 | 47,990 | 47,990 | - | - | Restricted Stock Units | |
| Axsome Therapeutics Inc | Mark Jacobson | CHIEF OPERATING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Nov 2021 | 41,638 | 41,638 | - | - | Employee Stock Option (Right to Buy) | |
| Axsome Therapeutics Inc | Mark Jacobson | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Mar 2021 | 41,638 | 41,638 | - | - | Employee Stock Option (Right to Buy) | |
| Axsome Therapeutics Inc | Mark Jacobson | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Mar 2021 | 22,163 | 22,163 | - | - | Restricted Stock Units |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges